Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tislelizumab and Capecitabine in High-risk Nasopharyngeal Carcinoma
NCT05342792Phase 3Recruiting
- Sponsor
- Sun Yat-sen University
- Start
- Apr 2022
- Primary completion
- Jun 2027
- Countries
- 1
01
Overview
A Phase 3 trial of tislelizumab in nasopharyngeal carcinoma (NPC), sponsored by Sun Yat-sen University. Started Apr 2022; status: recruiting.
02
Drugs
tislelizumab
03
Conditions
nasopharyngeal carcinoma (NPC)
Beyond the preview
Go deeper on NCT05342792.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05342792.